Immunotherapy biotech raises $37M from backers like Pfizer, Takeda, BMS
13 Dec 2023
Immunotherapy
Immunotherapy biotech EvolveImmune Therapeutics raised $37 million in a financing round, backed by big names like Pfizer and its newest investor, Bristol Myers Squibb.
EvolveImmune said it will use the funds to advance its lead T cell engager program, called EV-104, through preclinical studies and into humans in solid tumors. Its first-in-human clinical trials are expected to start in 2024. EV-104 was created using the company’s costimulatory T cell engager platform, dubbed EVOLVE. The company unveiled early data for the candidate in April, where it matched the asset against a CD3 bispecific antibody.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.